Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunorizon Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, so prosecution is concentrated in one examination setting.
PRIEST, JESSICA MARIE is the busiest examiner, with 1 pending matter. A targeted review of the examiner’s objections and the application’s support for its biotechnology claims should shape the response.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690788 | ANTI-ROR1 ANTIBODIES AND USES THEREOF | PRIEST, JESSICA MARIE | 1642 | §112 | Non-Final OA | — | Pending | Mar 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunorizon Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jessica Marie Priest has the most, with 1 of Immunorizon Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.